Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response

Li, Changyou; Zhu, Danni; Zhao, Yonghui; Guo, Qingming; Sun, Weihong; Li, Linxi; Gao, Daiqing; Zhao, Peng

doi:10.1080/08820139.2019.1696360

Cited by 10 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As cellular immunity plays an important role in antitumor immunity, ACT has become a powerful treatment strategy for cancers, including ovarian cancer (9,10). ACT of dendritic cells (DCs), the main antigen presenting cells, together with cytokine induced killer cells (CIKs), has shown great potential to prevent tumor recurrence, increase progression-free survival (PFS) rates, and improve the quality of life of cancer patients (11)(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer

Cheng

Wang

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Ovarian cancer is a leading cause of death among gynecological malignancies, and novel therapies are urgently needed. Here we report preliminary findings on the potential safety and efficacy of 6B11-OCIK, an adoptive cell therapy of autologous T cells induced by the humanized anti-idiotypic antibody 6B11 minibody plus dendritic cells and cytokines, against platinum-resistant recurrent or refractory ovarian cancer in three patients. We found that 6B11-OCIK treatment was safe and well tolerated after five cycles of intravenous infusion with an initial dose of 1–2×109 cells and a dose-climbing strategy. Hemoglobin, platelets, white cell count, creatinine or liver enzyme values, coagulation function, kidney and heart function were not significantly affected over the duration of therapy. Two of the three enrolled patients showed potentially drug-related grade 1 and 2 weakness, and no other adverse events were observed. Of the three enrolled patients, one had stable disease and two showed disease progression. The patient with favorable clinical efficacy had better immune response as measured by 6B11-OCIK proliferation capacity, activation ability of CD3+CD8+ tumor-specific cytotoxic T lymphocytes and CD3+CD56+ cytokine-induced killer cells, and tumor cell killing efficiency. Changes in circulating tumor cells after treatment were consistent with serum level CA125 in the patient with stable disease (both decreased), while differences were observed in the two patients with disease progression (increased CA125 in both and decreased CTC in the patient with better immune response), suggesting that variation of circulating tumor cells was more consistent with immune response and reflected efficacy directly. This preliminary study suggested that autologous 6B11-OCIK treatment was safe and had potential clinical efficacy against ovarian cancer. Patients with better immune response had more favorable efficacy. In addition to imaging, CA125 and immunophenotypes, CTC monitoring may represent a potential indicator of immunotherapy response.

show abstract

Section: Introductionmentioning

confidence: 99%

Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer

Cheng

Wang

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…A recent study compared the immune response induced by DC-CIK cell treatment and DC activated cytotoxic T cell (DC-ACT) treatment [ 31 ]. One-hundred-and-twelve patients with solid tumors (six with RCC) were assigned to the DC-CIK treatment group and 116 patients (six with RCC) were assigned to the DC-ACT group.…”

Section: Clinical Studies On Cik Cells For the Treatment Of Rccmentioning

confidence: 99%

Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma

Zhang

Ellinger

Ritter

et al. 2020

Cancers

View full text Add to dashboard Cite

There is growing interest in cytokine-induced killer (CIK) cells on the integrated therapy of patients with RCC, especially those in the late stage or refractory to conventional chemotherapy and radiotherapy. In this review, a total of 15 clinical studies including 681 patients enrolled in CIK cell immunotherapy were outlined. Three-hundred-and-eighty-two patients with RCC were treated with CIK cells alone or in combination with DC vaccination, targeted agents sunitinib or sorafenib, and the PD-1 inhibitor pembrolizumab. Significantly improved 3-year overall survival rate was reported in four trials, whereas remarkably longer median progression-free survival was observed in three studies. Adverse reactions were mild and usually controllable fever and fatigue. Besides, preclinical research progresses were reviewed to increase our understanding about the underlying mechanisms of CIK cell cytotoxicity and identify potential targets to enhance their anti-tumor activity. These studies suggest that CIK cell-based immunotherapy has potential clinical benefits with a good safety profile and could become a promising approach in the combined therapies of RCC patients. However, further large-scale studies are required to evaluate the clinical efficacy of CIK cells and more efforts should be performed to identify the optimal CIK cell-based therapeutic regimen for RCC patients.

show abstract

“…Induction of a regulated host immune response against pathogens in general, and SARS-CoV-2 in particular, is essential to controlling and eliminating infection by employing adaptive and innate immune responses. Table 1 outlines the immune response of the human body to SARS COV-2 (Huang et al 2020 ; Li et al 2020 ; Liu et al 2020 ; Qin et al 2020 ; Tan et al 2021 ; Wen et al 2020 ). Efforts to decrease this virus’s distribution have been challenging because of gaps in information regarding disease pathogenesis, host immune responses, and therapeutic interventions.…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2: Unique Challenges of the Virus and Vaccines

Mahmoodpoor

Sanaie

Samadi

et al. 2021

Immunological Investigations

View full text Add to dashboard Cite

In November 2019, the highly infectious coronavirus SARS-CoV-2 emerged in Wuhan, China, and has since spread to almost all countries worldwide. Since its emergence, the COVID-19 infection has led to significant public health, economic and social problems. The current pandemic has inspired researchers to make every effort to design and develop an effective COVID-19 vaccine to provide sufficient protection against the virus and control the infection. In December 2020, the Pfizer vaccine was the first COVID-19 vaccine given Emergency Use Authorization (EUA), and the second FDA so-approved vaccine was the Moderna mRNA-1273 vaccine, which was introduced a week later. Both Pfizer and Moderna vaccines are mRNA-based vaccines, and are estimated to have an efficacy rate of more than 94%. The aim of this article is to provide a review of the attempts made to develop safe SARS-CoV-2 vaccines, highlighting potential challenges and concerns, such as disease enhancement, virus mutations, and public acceptance of the vaccine.

show abstract

Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response

Cited by 10 publications

References 32 publications

Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer

Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer

Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma

SARS-CoV-2: Unique Challenges of the Virus and Vaccines

Contact Info

Product

Resources

About